IL195493A0 - Combination preparations comprising bifeprunox and l-dopa - Google Patents

Combination preparations comprising bifeprunox and l-dopa

Info

Publication number
IL195493A0
IL195493A0 IL195493A IL19549308A IL195493A0 IL 195493 A0 IL195493 A0 IL 195493A0 IL 195493 A IL195493 A IL 195493A IL 19549308 A IL19549308 A IL 19549308A IL 195493 A0 IL195493 A0 IL 195493A0
Authority
IL
Israel
Prior art keywords
bifeprunox
dopa
combination preparations
preparations
combination
Prior art date
Application number
IL195493A
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of IL195493A0 publication Critical patent/IL195493A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
IL195493A 2006-06-16 2008-11-25 Combination preparations comprising bifeprunox and l-dopa IL195493A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81405206P 2006-06-16 2006-06-16
EP06115587 2006-06-16
PCT/EP2007/055956 WO2007144422A2 (en) 2006-06-16 2007-06-15 Combination preparations comprising bifeprunox and l-dopa

Publications (1)

Publication Number Publication Date
IL195493A0 true IL195493A0 (en) 2009-09-01

Family

ID=38691894

Family Applications (1)

Application Number Title Priority Date Filing Date
IL195493A IL195493A0 (en) 2006-06-16 2008-11-25 Combination preparations comprising bifeprunox and l-dopa

Country Status (9)

Country Link
EP (1) EP2037964A2 (en)
JP (1) JP2009539942A (en)
KR (1) KR20090033871A (en)
AU (1) AU2007259256A1 (en)
CA (1) CA2654557A1 (en)
EA (1) EA014576B1 (en)
IL (1) IL195493A0 (en)
NO (1) NO20090165L (en)
WO (1) WO2007144422A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009265760B2 (en) * 2008-06-30 2013-07-18 Novartis Ag Combinations comprising mGluR modulators for the treatment of parkinson's disease
ITMI20100260A1 (en) * 2010-02-19 2011-08-20 Giulio Scigliano PHARMACEUTICAL COMPOSITION CONTAINING A DRUG TO REDUCE THE SIDE EFFECTS OF ANTIPSYCHOTIC DRUGS
RU2611376C2 (en) * 2010-10-15 2017-02-21 Контера Фарма Апс Pharmaceutical composition for treating, preventing or relieving movement disorders and its application
HUE037732T2 (en) * 2012-04-18 2018-09-28 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders
PT3209302T (en) 2014-10-21 2019-07-19 Abbvie Inc Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
WO2018011181A1 (en) 2016-07-11 2018-01-18 Contera Pharma Aps Pulsatile drug delivery system for treating morning akinesia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045362A1 (en) * 2003-08-18 2005-10-26 Solvay Pharm Bv STABLE CRYSTALLINE FORM OF BIFEPRUNOX MESILATE (MONOMETANSULFONATE 7- [4 - ([1,1- BIFENIL] -3- ILMETIL) -1- PIPERAZINIL] - 2- (3H) -BENZOXAZOLONA

Also Published As

Publication number Publication date
CA2654557A1 (en) 2007-12-21
JP2009539942A (en) 2009-11-19
AU2007259256A1 (en) 2007-12-21
WO2007144422A2 (en) 2007-12-21
WO2007144422A3 (en) 2008-03-13
EA200970022A1 (en) 2009-06-30
NO20090165L (en) 2009-01-12
EP2037964A2 (en) 2009-03-25
KR20090033871A (en) 2009-04-06
EA014576B1 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
IL194688A0 (en) Rapid acting and long acting insulin combination formulations
HK1138188A1 (en) Solid preparation comprising alogliptin and pioglitazone
ZA200810790B (en) Stable laquinimod preparations
EP2039347A4 (en) Cosmetic hair preparation
EP1951762A4 (en) Compositions and methods for improved skin care
PL2059223T3 (en) Skin care composition
HK1244819A1 (en) Foxm1 peptide and medicinal agent comprising the same
IL194751A0 (en) Drugs and uses
EP1879449A4 (en) Compositions and methods for skin care
GB0516069D0 (en) Pharmaceutical and use thereof
GB2443336B (en) Spiruchostatin analogues and their medicinal use
IL193700A0 (en) Medicaments and proteins
PL2066408T3 (en) Xanthoxyline-based composition and cosmetic use thereof
GB0615635D0 (en) Immunogenic proteins and uses thereof
EP2077262A4 (en) Iminopyridine derivative and use thereof
IL195493A0 (en) Combination preparations comprising bifeprunox and l-dopa
PL2012805T3 (en) Therapeutic composition and use
IL186337A0 (en) Stannsoporfin compositions and administration
IL191892A0 (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
ZA200900960B (en) Arylpiperazine derivatives and uses thereof
IL195532A0 (en) Combination preparations comprising slv308 and a l-dopa
EP1865777A4 (en) Stannsoporfin compositions and administration
EP2042153A4 (en) Skin cosmetic
ZA200810238B (en) Combination preparations comprising bifeprunox and L-DOPA
ZA200810239B (en) Combination preparations comprising SLV308 and a L-Dopa